Dace Pjanova

Title: Dace Pjanova: Innovator in Oncolytic Virus Research

Introduction

Dace Pjanova is a notable inventor based in Riga, Latvia. He has made significant contributions to the field of biotechnology, particularly in the development of oncolytic viruses for cancer treatment. With a focus on innovative methods for manufacturing genetically stable viruses, Pjanova's work has the potential to impact cancer therapies significantly.

Latest Patents

Dace Pjanova holds 2 patents related to genetically stable oncolytic RNA viruses. His latest patent describes a method for manufacturing a modified enterovirus of ECHO 7 type. This method involves the adaptation of the native ECHO 7 virus, which is isolated from human feces and identified by genome sequence. The process begins with the adaptation of the virus in cancer cells, which are treated with the anti-cancer agent dacarbazine. The modified virus is then passaged in human embryonal fibroblast culture, followed by propagation in human melanoma cells. Further passaging occurs in fibroblast culture treated with ribavirin, leading to the isolation and purification of the modified virus. This innovative approach aims to create a virus suitable for treating various tumors.

Career Highlights

Throughout his career, Dace Pjanova has worked with several companies, including Ditesan Ltd. and SIA Latima. His experience in these organizations has contributed to his expertise in the field of biotechnology and oncolytic virus research.

Collaborations

Dace Pjanova has collaborated with notable coworkers, including Dite Venskus and Ivars Kalvins. These collaborations have likely enriched his research and development efforts in the field.

Conclusion

Dace Pjanova's innovative work in the development of oncolytic viruses showcases his commitment to advancing cancer treatment methodologies. His patents and career achievements reflect a dedication to improving therapeutic options for patients facing cancer.